Phathom Pharmaceuticals, Inc. (PHAT) Securities Fraud Investigation - Levi & Korsinsky
NEW YORK CITY, NY / ACCESS Newswire / July 31, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Phathom Pharmaceuticals, Inc. ("Phathom Pharmaceuticals, Inc.") (NASDAQ:PHAT) concerning potential violations of the federal securities laws.
Phathom Pharmaceuticals, Inc. shareholders took the hit when Phathom Pharmaceuticals cut FY 2026 revenue guidance to $300 million-$325 million from the $320 million-$345 million range management had reaffirmed only weeks earlier, removing $20 million from both the bottom and top ends of its outlook.
On the February 26, 2026 Q4 2025 earnings call, President and CEO Steve Basta stated: "Our $320 million to $345 million revenue guidance for 2026 reflects our operating expectation of continued solid growth from our GI-focused strategy." On the April 30, 2026 Q1 2026 call, CFO Sanjeev Narula told investors, "We continue to anticipate 2026 net revenue between $320 million to $345 million," and Mr. Basta added, "We are thus maintaining our revenue guidance for the year."
On that same April 30 call, Mr. Basta described a commercial build carrying that guidance -- "We have more than 290 reps in place to start Q2" -- while Mr. Narula described the Company's gross-to-net discount landing at the lower end of a 55% to 59% range. Weeks later, the top end of the revenue range came down by $20 million.
If you suffered a loss on your Phathom Pharmaceuticals, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171
SOURCE: Levi & Korsinsky, LLP